TMDX — TransMedics Group Inc

TransMedics Group Inc (TMDX) is a medical devices company listed on NASDAQ. It is led by Waleed H. Hassanein M.D., based in 200 Minuteman Road, Andover, MA, United States, 01810, with about 898 employees. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Latest reported TMDX revenue for 2025-09-30 was $143.8M. Net income was $84.9M. Revenue was down 8.6% from 2025-06-30 to 2025-09-30. TMDX currently screens at market cap $2.53B and trailing P/E 16.8.

Use this TMDX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TMDX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TMDX SEC filings page. Lician reads the product cache first so this HTML stays unique to TransMedics Group Inc even when a live quote feed is slow.